Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TDS Pharm Co's total inventories for the quarter that ended in Jun. 2026 was ₩3,977 Mil. TDS Pharm Co's average total inventories from the quarter that ended in Mar. 2026 to the quarter that ended in Jun. 2026 was ₩3,607 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. TDS Pharm Co's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was ₩2,767.40.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
TDS Pharm Co's Days Inventory for the
three
months ended in Jun. 2026 was 53.35.
Inventory Turnover measures how fast the company turns over its inventory within a year.
TDS Pharm Co's Inventory Turnover for the quarter that ended in Jun. 2026 was 1.71.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
TDS Pharm Co's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.45.
TDS Pharm Co (XKRX:464280) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
TDS Pharm Co's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
TDS Pharm Co's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
TDS Pharm Co Total Inventories Related Terms
TDS Pharm Co Total Inventories Historical Data
* Premium members only.
The historical data trend for TDS Pharm Co's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
TDS Pharm Co (XKRX:464280) has a Total Inventories of ₩3,977 Mil as of Jun. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for TDS Pharm Co and its competitors.
Is TDS Pharm Co's Total Inventories too high?
TDS Pharm Co's current Total Inventories is ₩3,977 Mil. Overall, TDS Pharm Co has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does TDS Pharm Co's Total Inventories compare to LLY and JNJ?
TDS Pharm Co's Total Inventories of ₩3,977 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for TDS Pharm Co and its competitors. TDS Pharm Co's current Total Inventories is ₩3,977 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TDS Pharm Co stock overvalued right now?
TDS Pharm Co (XKRX:464280) has a current Total Inventories of ₩3,977 Mil. The current Total Inventories is ₩3,977 Mil. TDS Pharm Co's overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For TDS Pharm Co (XKRX:464280), the current Total Inventories is ₩3,977 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.
40GF Score
Get the complete analysis for XKRX:464280
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:464280 has been successfully added to your 
